Quantbot Technologies LP Acquires New Position in Boston Scientific Corporation $BSX

Quantbot Technologies LP bought a new position in shares of Boston Scientific Corporation (NYSE:BSX) during the 2nd quarter, HoldingsChannel.com reports. The fund bought 235,949 shares of the medical equipment provider’s stock, valued at approximately $10,070,000. Boston Scientific makes up 0.4% of Quantbot Technologies LP’s investment portfolio, making the stock its 28th largest position.

Other hedge funds also recently added to or reduced their stakes in the company. Renaissance Group LLC purchased a new position in Boston Scientific in the fourth quarter worth approximately $28,064,000. Perigon Wealth Management LLC acquired a new position in Boston Scientific during the 2nd quarter worth approximately $883,000. Y Intercept Hong Kong Ltd increased its position in shares of Boston Scientific by 148.8% in the 2nd quarter. Y Intercept Hong Kong Ltd now owns 1,120,331 shares of the medical equipment provider’s stock valued at $47,816,000 after purchasing an additional 670,060 shares during the last quarter. PensionDanmark Pensionsforsikringsaktieselskab raised its holdings in shares of Boston Scientific by 9.9% in the 2nd quarter. PensionDanmark Pensionsforsikringsaktieselskab now owns 320,038 shares of the medical equipment provider’s stock valued at $13,659,000 after purchasing an additional 28,961 shares in the last quarter. Finally, Meiji Yasuda America Inc acquired a new stake in shares of Boston Scientific in the 4th quarter valued at $4,708,000. 89.07% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, CEO Michael F. Mahoney purchased 186,240 shares of the company’s stock in a transaction that occurred on Monday, August 3rd. The shares were purchased at an average price of $48.33 per share, for a total transaction of $9,000,979.20. Following the purchase, the chief executive officer directly owned 1,590,024 shares of the company’s stock, valued at $76,845,859.92. This represents a 13.27% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director David C. Habiger purchased 2,100 shares of the business’s stock in a transaction on Wednesday, August 5th. The shares were purchased at an average cost of $47.59 per share, for a total transaction of $99,939.00. Following the transaction, the director owned 17,160 shares of the company’s stock, valued at $816,644.40. This trade represents a 13.94% increase in their ownership of the stock. Additional details regarding this purchase are available in the official SEC disclosure. In the last three months, insiders bought 194,522 shares of company stock valued at $9,385,210. Insiders own 0.34% of the company’s stock.

Wall Street Analyst Weigh In

A number of equities analysts recently commented on the stock. BTIG Research lowered their target price on shares of Boston Scientific from $65.00 to $60.00 and set a “buy” rating for the company in a research note on Wednesday, July 29th. Needham & Company LLC cut their price target on Boston Scientific from $77.00 to $57.00 and set a “buy” rating on the stock in a research note on Wednesday, July 8th. Barclays decreased their price target on Boston Scientific from $96.00 to $89.00 and set an “overweight” rating for the company in a report on Thursday, May 28th. Robert W. Baird set a $56.00 price objective on Boston Scientific in a research report on Thursday, July 30th. Finally, Stifel Nicolaus set a $60.00 price objective on Boston Scientific in a report on Wednesday, July 29th. Twenty-four investment analysts have rated the stock with a Buy rating, five have assigned a Hold rating and two have issued a Sell rating to the company’s stock. According to data from MarketBeat, Boston Scientific has an average rating of “Moderate Buy” and a consensus target price of $71.62.

Boston Scientific Trading Up 2.1%

NYSE BSX opened at $50.39 on Friday. The firm’s fifty day moving average price is $46.34 and its 200 day moving average price is $57.86. Boston Scientific Corporation has a 12 month low of $42.20 and a 12 month high of $109.50. The company has a debt-to-equity ratio of 0.43, a current ratio of 1.24 and a quick ratio of 0.74. The company has a market capitalization of $73.03 billion, a price-to-earnings ratio of 20.40, a price-to-earnings-growth ratio of 1.10 and a beta of 0.56.

Boston Scientific (NYSE:BSX) last announced its quarterly earnings results on Wednesday, July 29th. The medical equipment provider reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.83 by $0.03. Boston Scientific had a net margin of 17.50% and a return on equity of 19.28%. The firm had revenue of $5.44 billion during the quarter, compared to analysts’ expectations of $5.38 billion. During the same period in the previous year, the company earned $0.75 earnings per share. Boston Scientific’s quarterly revenue was up 7.5% compared to the same quarter last year. Boston Scientific has set its Q3 2026 guidance at 0.800-0.820 EPS and its FY 2026 guidance at 3.280-3.320 EPS. On average, sell-side analysts expect that Boston Scientific Corporation will post 3.3 earnings per share for the current fiscal year.

Boston Scientific declared that its Board of Directors has approved a share repurchase plan on Monday, May 18th that allows the company to repurchase $5.00 billion in outstanding shares. This repurchase authorization allows the medical equipment provider to purchase up to 6.4% of its shares through open market purchases. Shares repurchase plans are often a sign that the company’s board of directors believes its stock is undervalued.

About Boston Scientific

Boston Scientific Corporation (NYSE: BSX) is a global medical device company that develops, manufactures and markets a broad portfolio of products used in less-invasive medical procedures. Founded in 1979 by John Abele and Peter Nicholas, the company is headquartered in Marlborough, Massachusetts, and focuses on technologies that enable physicians to treat a wide range of cardiovascular, digestive, urologic, pulmonary and chronic pain conditions without open surgery.

Boston Scientific’s activities span product development, clinical research, regulatory affairs and commercial sales.